Advances in Targeting Cancer-Associated Genes by Designed siRNA in Prostate Cancer

SIMPLE SUMMARY: Despite great advancements in early detection and therapeutic strategies, the 5-year survival rate for patients with metastatic prostate cancer remains low (i.e., ~30%). Targeting prostate cancer-associated genes has emerged as a promising treatment for this devastating disease. This...

Descripción completa

Detalles Bibliográficos
Autores principales: Bahreyni, Amirhossein, Luo, Honglin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761674/
https://www.ncbi.nlm.nih.gov/pubmed/33287240
http://dx.doi.org/10.3390/cancers12123619

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761674/
https://www.ncbi.nlm.nih.gov/pubmed/33287240
http://dx.doi.org/10.3390/cancers12123619

Ejemplares similares